Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Dec;11(12):669-70.
doi: 10.1038/nrneurol.2015.218. Epub 2015 Nov 3.

Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?

Sam Gandy  1 , Mary Sano  1
Affiliations
Comment

Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?

Sam Gandy et al. Nat Rev Neurol. 2015 Dec.

Abstract

A treatment trial of the monoclonal anti-amyloid antibody solanezumab showed slight benefits in people with dementia due to mild Alzheimer disease. Drug effects on several neuropsychological testing outcomes were statistically significant, but the effect sizes were unlikely to manifest as meaningful functional benefits. Here, we discuss the implications and possible molecular underpinnings.

PubMed Disclaimer

Conflict of interest statement

Competing interests

Within the past 5 years, S.G. has provided consultation to the Janssen Pfizer Immunotherapy Alliance and has held grants from Baxter, Amicus and Constellation/Polyphenolics. M.S. has provided consultation to Janssen Pharmaceuticals, Eli Lilly, Eisai, Medivation, Sanofi Aventis, Biogen and Takeda. She has also consulted for Merck and Nutricia without any compensation.

Comment on

References

    1. Siemers ER, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. http://dx.doi.org/10.1016/j.jalz.2015.06.1893. - DOI - PubMed
    1. Liu E, et al. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015;85:692–700. - PMC - PubMed
    1. Jansen WJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313:1924–1938. - PMC - PubMed
    1. Jack CR, Jr, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732–1740. - PMC - PubMed
    1. Lambert MP, et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448–6453. - PMC - PubMed

Publication types

Substances